REPROCELL Corporate News
News about Stem Cells
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
Yokohama Japan, 25 May 2023: We are pleased to announce the results of the Phase II clinical trial in Japan (protocol number: RS-01) of our regenerative medicine product Stemchymal® (allogeneic adipose-derived mesenchymal stem cells) for the treatment of spinocerebellar ataxia, as follows.
25 May 2023 • Stem Cells
REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products
Yokohama Japan, 23 May 2023: REPROCELL will now offer CDMO services to manufacture Advanced Therapies Medicinal Products (ATMPs) generated from mesenchymal stem cells (MSC) through a partnership with Histocell.
23 May 2023 • Stem Cells
REPROCELL invests in Histocell, S.L. a Spain-based CDMO
Yokohama Japan, 23 November 2022: REPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem cell (iPSC) service offerings.
23 November 2022 • Stem Cells
REPROCELL is On the Road at ISSCR 2022
This June, REPROCELL’s experts will be busy. We will be joining with stem cell scientists at ISSCR 2022 to allow scientists an opportunity to meet in person with REPROCELL’s experts at Booth 310 and discuss how we can help solve complex problems in Drug Discovery and Regenerative Medicine.
7 June 2022 • Stem Cells
New publication on RNA reprogramming of endothelial progenitor cells to make clinically -relevant iPSCs
[Glasgow, UK] REPROCELL has contributed to a novel publication detailing advancements in induced pluripotent stem cell (iPSC) reprogramming. The paper, published in New Biotechnology by Dr Amer Rana and his team of researchers from the University of Cambridge, was in collaboration with Dr Sarah Eminli-Meissner, Head of Business for Stem Cell Research at REPROCELL. It describes techniques for reprogramming blood-derived cells endothelial progenitor cells, or “EPCs”, into iPSCs.
1 March 2021 • Stem Cells
Axion BioSystems makes REPROCELL a distributor of its Maestro systems and consumables
[Hyderabad, India] Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced Bioserve Biotechnologies Pvt Ltd (REPROCELL’s 100% owned subsidiary) as the new distributor of its Maestro systems and consumables in India.
16 February 2021 • Stem Cells
REPROCELL announce the launch of StemRNA™ Entero human iPSC-derived intestinal epithelial cells
Yokahoma, Japan: REPROCELL announce the launch of StemRNA™ Entero: human iPSC-derived intestinal epithelial cells.
StemRNA™ Entero cells are intestinal epithelial cells derived from human iPSCs. This model was developed using advanced technologies established by Professor Shoen Kume (The Tokyo Institute of Technology) and REPROCELL, Inc. StemRNA™ Entero cells closely mimic the gene expression of intestinal epithelial cells; for example, they express high levels of the CYP3A4 gene – a key enzyme for metabolism – compared to Caco2 cells, an intestinal model system widely used to measure the absorption and metabolism of novel therapeutics. StemRNA™ Entero cells are designed for use as a more clinically relevant alternative to Caco2 cells in drug development.
15 July 2020 • Stem Cells